Antiepileptic drugs as analgesics/adjuvants in inflammatory pain: current preclinical evidence
M Tomić, U Pecikoza, A Micov, S Vučković… - Pharmacology & …, 2018 - Elsevier
Inflammatory pain is the most common type of pain that is treated clinically. The use of
currently available treatments (classic analgesics-NSAIDs, paracetamol and opioids) is …
currently available treatments (classic analgesics-NSAIDs, paracetamol and opioids) is …
Antiepileptics and the treatment of neuropathic pain: evidence from animal models
G Blackburn-Munro, HK Erichsen - Current pharmaceutical …, 2005 - ingentaconnect.com
Neuropathic pain is characterised by both positive (hyperalgesia and allodynia) and
negative (sensory deficits) symptoms and remains intractable to many commonly used …
negative (sensory deficits) symptoms and remains intractable to many commonly used …
Neurobiology of neuropathic pain: mode of action of anticonvulsants
AH Dickenson, EA Matthews, R Suzuki - European journal of pain, 2002 - Elsevier
Anticonvulsants are widely used for the treatment of neuropathic pain. Here we review the
evidence for a number of peripheral and central changes after nerve injury that may provide …
evidence for a number of peripheral and central changes after nerve injury that may provide …
Current status of the new antiepileptic drugs in chronic pain
HS Sidhu, A Sadhotra - Frontiers in pharmacology, 2016 - frontiersin.org
Antiepileptic drugs (AEDs) are extensively used worldwide to treat a wide range of disorders
other than epilepsy, such as neuropathic pain, migraine, and bipolar disorder. Due to this …
other than epilepsy, such as neuropathic pain, migraine, and bipolar disorder. Due to this …
Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy
IW Tremont-Lukats, C Megeff, MM Backonja - Drugs, 2000 - Springer
Neuropathic pain, a form of chronic pain caused by injury to or disease of the peripheral or
central nervous system, is a formidable therapeutic challenge to clinicians because it does …
central nervous system, is a formidable therapeutic challenge to clinicians because it does …
Anticonvulsants in neuropathic pain: rationale and clinical evidence
TS Jensen - European Journal of Pain, 2002 - Elsevier
Neuropathic pain, whether of peripheral or central origin, is characterized by a neuronal
hyperexcitability in damaged areas of the nervous system. In peripheral neuropathic pain …
hyperexcitability in damaged areas of the nervous system. In peripheral neuropathic pain …
Anticonvulsants: aspects of their mechanisms of action
B Söderpalm - European Journal of Pain, 2002 - Elsevier
An ideal anticonvulsant drug would prevent or inhibit excessive pathological neuronal
discharge without interfering with physiological neuronal activity and without producing …
discharge without interfering with physiological neuronal activity and without producing …
Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine
M Pappagallo - Clinical therapeutics, 2003 - Elsevier
Background: Both neuropathic pain and migraine are now being treated with a variety of
newer antiepileptic drugs (AEDs). The proven efficacy of gabap in postherpetic neuralgia …
newer antiepileptic drugs (AEDs). The proven efficacy of gabap in postherpetic neuralgia …
The efficacy of eslicarbazepine acetate in models of trigeminal, neuropathic, and visceral pain: the involvement of 5-HT: 1B/1D: serotonergic and CB: 1:/CB: 2 …
MA Tomic, UB Pecikoza, AM Micov… - Anesthesia & …, 2015 - journals.lww.com
BACKGROUND: Many clinical pain states that are difficult to treat share a common feature of
sensitization of nociceptive pathways. Drugs that could normalize hyperexcitable neural …
sensitization of nociceptive pathways. Drugs that could normalize hyperexcitable neural …
Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety
G Munro, HK Erichsen, NR Mirza - Neuropharmacology, 2007 - Elsevier
Signs and symptoms of persistent pain are associated with neuronal hyperexcitability within
nociceptive pathways. This manifests behaviourally as a decrease in the nociceptive …
nociceptive pathways. This manifests behaviourally as a decrease in the nociceptive …